The administration of HIF-PHIs to patients with CKD was consistently associated with decreased plasma hepcidin levels in phase 2 and phase 3 clinical trials [40,42,46,53,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84]. Here, HAMP is linked to chronic kidney disease.